CNP-201 not checked
COUR Pharmaceutical Development Company, Inc.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.”In the company’s words, NCT04950504 on ClinicalTrials.gov
- Tested for
- Peanut Allergy (2 trials)
- Main trialPhase 1
- “This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in Part B.”In the company’s words, NCT04950504 on ClinicalTrials.gov
Other drugs for Peanut Allergy
- Viaskin PeanutDBV Technologies · Phase 3
- RemibrutinibNovartis · Phase 3
- UKK-0018Ukko Inc · Phase 1/2
- RPT904RAPT Therapeutics, Inc., a member of the GSK plc group of companies · Phase 2
- ENP-501N-Fold, LLC · Phase 1/2
- LP-003Longbio Pharma · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 24 Jun 2022 | Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy | |
| Phase 1Terminated | 12 Dec 2023 | CNP-201 in Subjects With Peanut Allergy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026